Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Keiichiro Kawakami is active.

Publication


Featured researches published by Keiichiro Kawakami.


Pathology Research and Practice | 2003

Disappearance of CD21-positive Follicular Dendritic Cells Preceding the Transformation of Follicular Lymphoma: Immunohistological Study of the Transformation Using CD21, p53, Ki-67, and P-glycoprotein

Eisuke Shiozawa; Toshiko Yamochi-Onizuka; Tadanori Yamochi; Yutsuki Yamamoto; Hideki Naitoh; Keiichiro Kawakami; Tsuyoshi Nakamaki; Shigeru Tomoyasu; Miki Kushima; Hidekazu Ota

Some follicular lymphomas histologically transform into diffuse aggressive lymphomas, the prognosis of which is poor. There are, however, no reliable histological criteria for predicting which cases will later undergo such transformation. In low-grade B-cell lymphomas, follicular dendritic cells form dense mesh-like networks that contain accumulating neoplastic B-cells. These are rare in high-grade lymphomas. We immunohistochemically analyzed CD21-positive follicular dendritic cells in 32 follicular lymphomas, including 3 transformed lymphomas, in addition to immunohistological study using P-glycoprotein, p53, and Ki-67. We found that the mesh-like networks in follicles are more clearly defined in low-grade lymphomas than in high-grade lymphomas (p = 0.015). Neoplastic follicles in 2 transformed lymphomas lost the networks of follicular dendritic cells before transformation despite the existence of morphologically clear follicles. This differed from the non-transformed cases of the same cytological grades. Prognosis was statistically better for patients with low-grade tumor than for those with high-grade tumor (p = 0.026), and there was a trend toward poorer survival among CD21-negative cases (p = 0.186). P-glycoprotein, p53, and Ki-67 expressions did not provide sufficient information to predict the transformation of follicular lymphoma. The presence of CD21-positive follicular dendritic cells in neoplastic follicles might help predict the potential of follicular lymphoma to transform to diffuse large B-cell lymphoma.


British Journal of Haematology | 2003

Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival

Tsuyoshi Nakamaki; Yasuharu Hamano; Jun-ichi Hisatake; Akihiro Yokoyama; Keiichiro Kawakami; Shigeru Tomoyasu; Yoshio Honma; Phillip H. Koeffler

Summary. Cyclin A (A2) and cyclin A1 are members of the G2 cyclins, which are involved in the control of G2/M and G1/S transitions as well as mitosis. Human cyclin A1 was cloned as an A‐type cyclin that is highly expressed in acute myeloid leukaemia (AML). The clinical significance of these cyclins in myeloid leukaemia remains to be clarified. We investigated the relative levels of these transcripts in 80 patients with de novo AML. Correlations with clinical parameters showed that the initial white blood cell count and serum lactate dehydrogenase levels were inversely associated with cyclin A (A2) mRNA levels (r = −0·276, P = 0·019) and cyclin A1 mRNA levels (r = −0·241, P = 0·042) respectively. They were independently associated with increased overall survival [P = 0·035 for cyclin A (A2) and P = 0·016 for cyclin A1]. Multivariate analysis using Coxs proportional hazard model showed that elevated cyclin A1 mRNA levels contributed significantly to the better prognosis of patients with AML. Furthermore, the analysis of survival probability showed that the group with high levels of both cyclin A (A2) and A1 survived significantly longer than the group with low expression of both these cyclins (P = 0·002). These data indicate that high expression levels of both cyclin A (A2) and A1 are associated with good prognosis in AML patients.


Annals of Hematology | 1993

Spontaneous IL-2 production in vitro in two patients with pure red cell aplasia

Taijiro Ishiyama; Akimoto Y; Hideyuki Ueno; Keiichiro Kawakami; Michiaki Koike; Shigeru Tomoyasu; Nobuyoshi Tsuruoka

SummaryWe investigated spontaneous cytokine production in two patients with pure red cell aplasia (PRCA). The peripheral blood mononuclear cells (PBMNC) from two patients produced IL-2. Cyclosporin A (CyA) suppressed in vitro IL-2 production in one patient, but not in the other. Spontaneous IL-2 production disappeared in one patient 10 months after the start of CyA therapy. The patient for whom CyA therapy was stopped after the disappearance of spontaneous IL-2 production has remained in continuous remission for 1 year. The present case suggests that spontaneous IL-2 production in PBMNC might be an indicator of disease activity.


Pathology International | 2007

Histopathological bone marrow changes after reduced‐intensity hematopoietic stem cell transplantation for follicular lymphoma involving bone marrow

Takashi Maeda; Eisuke Shiozawa; Bungo Saito; Takako Usui; Hidetoshi Nakashima; Norimichi Hattori; Daisuke Adachi; Kouji Yanagisawa; Keiichiro Kawakami; Tsuyoshi Nakamaki; Shigeru Tomoyasu; Toshiko Yamochi-Onizuka; Masafumi Takimoto; Hidekazu Ota

Allogeneic stem cell transplantation (allo‐SCT) is used as curative therapy for malignant lymphoma, and reduced‐intensity hematopoietic stem cell transplantation (RIST) is sometimes performed to avoid the toxicity and mortality associated with myeloablative allo‐SCT. RIST is generally preferred for elderly patients with malignant lymphoma. A 62‐year‐old woman with follicular lymphoma (FL) involving bone marrow (BM) suffered relapse after autologous SCT. RIST was performed; cells were from an unrelated, fully human leukocyte antigen‐matched donor. To study the hematopoietic reconstitution, BM biopsy specimens that were obtained at different times after RIST, were evaluated. Engraftment of donor cells was observed on days 19 and 48 after RIST, and residual FL in BM had completely disappeared by day 73 after RIST. This is the first report to document histological BM regeneration after RIST and disappearance of FL involving the BM.


American Journal of Hematology | 2007

Reversible posterior leukoencephalopathy syndrome after repeat intermediate‐dose cytarabine chemotherapy in a patient with acute myeloid leukemia

Bungo Saito; Tsuyoshi Nakamaki; Hidetoshi Nakashima; Takako Usui; Norimichi Hattori; Keiichiro Kawakami; Shigeru Tomoyasu


Leukemia Research | 2006

Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group

Eisuke Shiozawa; Masafumi Takimoto; Reiko Makino; Daisuke Adachi; Bungo Saito; Toshiko Yamochi-Onizuka; Tadanori Yamochi; Junko Shimozuma; Takashi Maeda; Yohko Kohno; Keiichiro Kawakami; Tsuyoshi Nakamaki; Shigeru Tomoyasu; Akira Shiokawa; Hidekazu Ota


The Japanese journal of clinical hematology | 2003

Acute myeloid leukemia originating from the same leukemia clone after the complete remission of acute lymphoid leukemia

Matsuda I; Tsuyoshi Nakamaki; Amaya H; Kiyosaki M; Keiichiro Kawakami; Yamada K; Yokoyama A; Ken-ichiro Hino; Shigeru Tomoyasu


The Japanese journal of clinical hematology | 1995

[Multicentric Castleman's disease with lymphoid interstitial pneumonia died of aggressive course with adult respiratory distress syndrome].

Akimoto Y; Taijiro Ishiyama; Keiichiro Kawakami; Ken-ichiro Hino; Shigeru Tomoyasu; Nobuyoshi Tsuruoka; Kushima M; Ota S; Kazama K


The Japanese journal of clinical hematology | 2003

[Hepatitis-associated aplastic anemia preceded by a hemophagocytic syndrome-like state].

Matsunawa M; Keiichiro Kawakami; Hisatake J; Suzuki J; Tsuyoshi Nakamaki; Ken-ichiro Hino; Shigeru Tomoyasu


Japanese Journal of Clinical Immunology | 2003

[Severe type of Epstein-Barr virus associated hemophagocytic syndrome successfully treated with T-COP-E and splenectomy].

Eisuke Shiozawa; Keiichiro Kawakami; Isao Matsuda; Tsuyoshi Nakamaki; Ken-ichiro Hino; Hidekazu Ota; Shigeru Tomoyasu

Collaboration


Dive into the Keiichiro Kawakami's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge